Evaluation of a Specialized Therapeutic Care of Patients Presenting an Intolerance Attributed to Electromagnetic Fields
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · May 13, 2013
Trial Information
Current as of May 06, 2025
Completed
Keywords
ClinConnect Summary
110 patients suffering from Idiopathic Environmental Intolerance attributed to electromagnetic fields (IEI-EMF) are expected in this trial.
Type of trial: Interventional multicenter study, non-randomized, with measurement before and after intervention. Each patient is his own control.
Primary outcome: Efficacy of an individual medical care on electro sensitive (IEI CEM) patients evaluated from the improvement of health status, sensitivity to electromagnetic fields (EMF) exposure, and quality of life.
Scheme:
Visit 1(T0): Patients undergo a specialized medical examination: a standardized...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects who declare themselves to be intolerant to electromagnetic fields
- • Subjects over 18 years old
- • Subjects affiliated to a social security scheme
- • Subjects who signed the consent form
- Exclusion Criteria:
- • Subject with a disorder of the understanding of the French language at the discretion of the investigator
- • Pregnant women,
- • Persons deprived of their liberty, persons under guardianship, and persons in emergency situations.
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Trial Officials
Lynda BENSEFA-COLAS, MD
Study Director
Service de Pathologie Professionnelle, Hopital Cochin, AP-HP, Paris
Rene de SEZE, MD
Study Director
INERIS (Institut National de l'EnviRonnement Industriel et des RisqueS)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials